Patents by Inventor Charles E. Rupprecht

Charles E. Rupprecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160114026
    Abstract: Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies.
    Type: Application
    Filed: December 22, 2015
    Publication date: April 28, 2016
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Xianfu Wu, Charles E. Rupprecht, Ivan V. Kuzmin
  • Patent number: 9248179
    Abstract: Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: February 2, 2016
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Xianfu Wu, Charles E. Rupprecht, Ivan V. Kuzmin
  • Patent number: 8865461
    Abstract: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: October 21, 2014
    Assignee: The United States of America as represtented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Charles E. Rupprecht, Xianfu Wu
  • Publication number: 20130095137
    Abstract: Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies.
    Type: Application
    Filed: June 23, 2011
    Publication date: April 18, 2013
    Applicant: The Government of the United States of America as Represented by the Secretary of the Department of
    Inventors: Xianfu Wu, Charles E. Rupprecht, Ivan V. Kuzmin
  • Publication number: 20110070264
    Abstract: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.
    Type: Application
    Filed: November 30, 2010
    Publication date: March 24, 2011
    Inventors: Charles E. Rupprecht, Xianfu Wu
  • Patent number: 7863041
    Abstract: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: January 4, 2011
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Charles E. Rupprecht, Xianfu Wu
  • Publication number: 20080274130
    Abstract: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.
    Type: Application
    Filed: October 13, 2006
    Publication date: November 6, 2008
    Applicant: The Govt. of the U.S.A. as Represented by the Secretary of the Dept.of Health and Human Services
    Inventors: Charles E. Rupprecht, Xianfu Wu
  • Patent number: 7074413
    Abstract: Live, attenuated recombinant rabies virus vaccines are generated using reverse genetics to combine the antigenic determinants that render the rabies virus non-pathogenic with the determinants that are responsible for the elicitation of an effective anti-rabies immune response. These vaccines do not affect the antigenic, and therefore the immunogenic, properties of the virus. The present invention further relates to recombinant rabies virus vaccines that express a pro-apoptotic protein, such as cytochrome c, to increase the capacity to induce apoptosis, thereby enhancing the protective immunity against rabies. This new generation of live rabies virus vaccines represents a safe and effective approach to the eradication of rabies in wildlife, and subsequently humans and livestock.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: July 11, 2006
    Assignee: Thomas Jefferson University
    Inventors: Bernhard Dietzschold, D. Craig Hooper, Matthias Schnell, Charles E. Rupprecht